EverSource Wealth Advisors LLC Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Key Points

• EverSource Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 24.7%, owning a total of 5,042 shares valued at approximately $4.17 million as of the latest SEC filing.
• Insider trading reports show that both CEO David A. Ricks and Director J. Erik Fyrwald purchased shares of the stock on August 12th, indicating confidence in the company's future potential.
• Eli Lilly recently reported earnings of $6.31 per share, exceeding analyst expectations, and announced a quarterly dividend of $1.50 per share, enhancing its appeal to investors.

EverSource Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 24.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,042 shares of the company's stock after purchasing an additional 999 shares during the period. EverSource Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $4,165,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the 1st quarter worth $40,000. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company during the 4th quarter worth $43,000. Finally, O Brien Wealth Partners LLC increased its stake in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Up 2.5%

LLY traded up $17.08 during midday trading on Friday, reaching $701.51. 8,211,278 shares of the company were exchanged, compared to its average volume of 6,346,453. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company's fifty day moving average price is $764.55 and its 200 day moving average price is $794.63. The company has a market cap of $663.95 billion, a price-to-earnings ratio of 45.85, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.92 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Leerink Partners reissued a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Guggenheim cut their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $964.88.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.